Subacute Sensorimotor Neuropathy Accompanied by Anti-ganglioside GM1 Antibody in a Patient with Lung Cancer

Intern Med. 2018 Nov 15;57(22):3289-3292. doi: 10.2169/internalmedicine.0667-17. Epub 2018 Jul 6.

Abstract

A 66-year-old man presented with subacute sensorimotor neuropathy in association with small cell lung cancer. Tests for the anti-ganglioside antibody GM1-IgM were positive. Chemotherapy and intravenous immunoglobulin treatment led to a slight improvement in neurological symptoms. Four additional cases of neuropathy accompanied by anti-ganglioside antibody and lung cancer have been reported. The most commonly reported pattern was subacute sensorimotor neuropathy. Patients died from cancer progression after 5 to 18 months. There is evidence that anti-ganglioside antibody inhibits tumor progression, prolonging the patient survival. However, severe neurological disturbance may offset the survival benefit of anti-ganglioside antibody in patients with paraneoplastic neurological syndrome.

Keywords: Guillain-Barré syndrome; ganglioside; lung cancer; neuropathy; paraneoplastic; small cell.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Autoantibodies / immunology*
  • G(M1) Ganglioside / immunology*
  • Guillain-Barre Syndrome / complications
  • Guillain-Barre Syndrome / immunology*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • Lung Neoplasms / complications*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Male
  • Small Cell Lung Carcinoma / complications*
  • Small Cell Lung Carcinoma / diagnosis
  • Small Cell Lung Carcinoma / drug therapy
  • Tomography, X-Ray Computed

Substances

  • Autoantibodies
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • G(M1) Ganglioside